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Rac1, a subunit of NADPH oxidase, plays an impor-
tant role in directed endothelial cell motility. We re-
ported previously that Rac1 activation was necessary
for choroidal endothelial cell migration across the
retinal pigment epithelium, a critical step in the de-
velopment of vision-threatening neovascular age-re-
lated macular degeneration. Here we explored the roles
of Rac1 and NADPH oxidase activation in response to
vascular endothelial growth factor treatment in vitro
and in a model of laser-induced choroidal neovascu-
larization. We found that vascular endothelial growth
factor induced the activation of Rac1 and of NADPH
oxidase in cultured human choroidal endothelial
cells. Further, vascular endothelial growth factor led
to heightened generation of reactive oxygen species
from cultured human choroidal endothelial cells,
which was prevented by the NADPH oxidase inhibi-
tors, apocynin and diphenyleneiodonium, or the an-
tioxidant, N-acetyl-L-cysteine. In a model of laser-in-
duced injury, inhibition of NADPH oxidase with
apocynin significantly reduced reactive oxygen spe-
cies levels as measured by dihydroethidium fluores-
cence and the volume of laser-induced choroidal neo-
vascularization. Mice lacking functional p47phox, a
subunit of NADPH oxidase, had reduced dihydro-
ethidium fluorescence and choroidal neovasculariza-
tion compared with wild-type controls. Taken to-
gether, these results indicate that vascular endothelial
growth factor activates Rac1 upstream from NADPH
oxidase in human choroidal endothelial cells and
increases generation of reactive oxygen species ,
contributing to choroidal neovascularization. These
steps may contributed to the pathology of neovas-
cular age-related macular degeneration. (Am J
Pathol 2010, 177:2091–2102; DOI: 10.2353/ajpath.2010.090878)
Age-related macular degeneration (AMD) is a leading
cause of visual impairment in elderly individuals1–4 and is
estimated to affect approximately 14 million people
worldwide.5 Ninety percent of legal blindness from AMD
is due to neovascularization that originates from endothe-
lial cells in the choroid and grows into neurosensory
retina as choroidal neovascularization (CNV).5 Although it
is recognized that genetic polymorphisms, such as those
involved in the alternative pathway of the complement
system, have been strongly associated with increased
risk of advanced AMD,6–11 AMD does not manifest at
birth but rather in the seventh or eighth decades of life.
The current thinking is that a genetic predisposition ac-
companied by exogenous, chronic, repeated stresses
could lead to tissue damage and dysfunction that be-
comes apparent only later in life.10,12,13 In support of this
theory is clinical evidence of independent and sometimes
additive risk of advanced AMD from environmental
factors.14
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Several environmental factors associated with increased
risk of AMD also increase oxidative stress. Examples in-
clude blue light-induced photochemically released oxi-
dants15 and cigarette smoke-related compounds.16 Other
clinical evidence supports oxidative stress in advanced
AMD. Proteomic analysis of Bruch’s membrane from human
eyes with AMD revealed the presence of oxidized com-
pounds.17 The Eye Disease Case Control Study found an
association between reduced prevalence of AMD and high
dietary intake of antioxidants.18 The placebo-controlled,
double-masked multicenter clinical Age-Related Eye Dis-
ease Study provided strong support for the relationship
between AMD and oxidants by finding reduced progres-
sion to advanced AMD and vision loss in subjects who took
certain antioxidants and zinc supplements.19
Laboratory evidence provides mechanistic support for
oxidative stress in the pathophysiology of AMD. Condi-
tioned media from hydrogen peroxide-treated retinal pig-
ment epithelium (RPE) induced an angiogenic phenotype in
cocultured choroidal endothelial cells.20 Glutathione-de-
pleted RPE, thus susceptible to oxidative damage, had
increased expression of vascular endothelial growth factor
(VEGF) and its receptors compared with the control.20 A
mouse model lacking the antioxidant enzyme, CuZn super-
oxide dismutase, developed features of AMD, namely
drusen, CNV, and dysfunction in RPE cell junctions and
barrier properties.21 Photo-oxidation of bis-retinoid lipofus-
cin in cultured RPE cells resulted in released complement
activation fragments, providing evidence that oxidation ac-
tivated complement and also linked photo-oxidative stress
and the complement system.22 Although evidence sup-
ports oxidative damage in AMD, gaps remain in our under-
standing of the steps involved in the pathophysiology of
advanced vision-threatening AMD.
We reported previously that activation of the small Rho
GTPase, Rac1, was necessary for choroidal endothelial
cell migration across the RPE, a critical step in the de-
velopment of neovascular AMD.23 Further, the activation
of Rac1 was found downstream of VEGF-VEGF receptor
2 signaling.24 Rac1 is important in directed endothelial
cell motility and is also an important subunit of the en-
zyme complex, NADPH oxidase. In its inactive state,
NADPH oxidase consists of membrane-bound subunits,
ie, gp91phox and p22phox, and cytosolic subunits,
p67phox and p47phox, in addition to Rac1 in endothelial
cells.25 When activated, the subunits aggregate and the
active enzyme generates reactive oxygen species (ROS)
and triggers angiogenic signaling in endothelial cells
(ECs).25 In this study, we investigated the role of NADPH
oxidase in the pathogenesis of CNV.
Materials and Methods
Reagents
VEGF165 was purchased from R&D Systems, (Minneap-
olis, MN). Apocynin, diphenyleneiodonium (DPI), and N-
acetyl-L-cysteine (NAC) were obtained from Sigma-Al-
drich (St. Louis, MO).
Cell Culture
Isolation of Human Choroidal Endothelial Cells
Choroidal endothelial cells (ECs) were obtained from
donor eyes of adults younger than 30 years of age from
the North Carolina Eye Bank, Inc. (Winston-Salem, NC).
Within 24 hours of death, the vitreous and retina were
removed from the eyecup. The RPE layer was removed
by repeated titration with Hanks’ balanced salt solution
(Invitrogen, San Diego, CA). The choroidal layer was
peeled from the sclera, minced into small pieces, and
washed with Hanks’ balanced salt solution. The pieces
were incubated with 500 g/ml collagenase 1A (Roche,
Nutley, NJ) and 1.2 U/ml Dispase (Invitrogen) for 45
minutes at 37°C with constant agitation. After digestion,
the segments were filtered through a 33-m mesh filter
(BD Biosciences, San Jose, CA). The enzymes were
neutralized with an equal volume of endothelial growth
media (EGM-2, Lonza, Walkersville, MD) with 10% fetal
bovine serum (FBS). The filtered cells were centrifuged at
400g at 4°C for 5 minutes and resuspended in 0.5 ml of
Hanks’ balanced salt solution with 5% FBS. The cells
were then incubated with CD31-coated Dynabeads (In-
vitrogen) for 30 minutes at room temperature with gentle
rotation. The CD31-positive cells were separated with the
Dynal Magnetic Particle Concentrator (Invitrogen). The
cells-bead complex was washed with Hanks’ balanced
salt solution/5% FBS and reapplied to the magnet. The
wash step was repeated five times. The cells were then
plated onto a T-75 flask in EGM-2 with 10% FBS at 37°C
with 5% CO2. EC identification was based on positive
staining for CD31, VE-cadherin, and von Willebrand fac-
tor and by uptake of acetylated low-density lipoprotein.
Choroidal ECs were maintained in EGM-2 with 10% FBS
and used through passage 4.
For in vitro studies, choroidal ECs were grown until 90%
confluence and were pretreated for 2 hours in serum-free
EBM-2 with 500 mol/L apocynin, 1 mmol/L NAC, 1
mol/L DPI, or PBS. Fifteen minutes before collection,
choroidal ECs were incubated in 10 ng/ml VEGF165 (R&D
Systems).
RPE Studies
Human ARPE-19 cells (American Type Culture Collec-
tion, Rockville, MD), up to passage 18, were grown to
80% confluence in Dulbecco’s modified Eagle’s medium-
Nutrient Mixture F-12 (DMEM/F12) (Invitrogen, Carlsbad,
CA) and supplemented with 10% FBS. These cells con-
stitutively produce greater amounts of VEGF than more
differentiated human fetal RPE and were chosen for this
experiment to mimic the conditions of neovascular AMD,
in which the RPE produces more VEGF than normal.26
ARPE-19 cells were pretreated for 6 hours with 500
mol/L apocynin, 2 mol/L DPI, or PBS in serum-free
medium. Immediately thereafter, cells were washed
with PBS, retreated, and placed into room air (21% O2)
for 16 hours. Cells were then washed with PBS, and
total RNA was purified using the RNeasy Mini kit (Qia-
gen, Valencia, CA).
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Real-Time Quantitative PCR
Assays were performed using the Applied Biosystems
7900HT Real-Time PCR System. In brief, 1 g of total RNA
was reverse-transcribed into cDNA using a TaqMan Re-
verse Transcription reagent (Applied Biosystems, Foster
City, CA), according to the manufacturer’s protocol. One-
twentieth of the total cDNA (50 ng of equivalent RNA) was
used in each amplification reaction. Each TaqMan reaction
(16 l) contained 5 l of cDNA, 8 l of TaqMan PCR
MasterMix (Applied Biosystems), 1 l of forward primer (5
mol/L), 1 l of reverse primer (5 mol/L), and 1 l of probe
(5 mol/L) (see below for primer sequences). PCR cycles
consisted of denaturation at 95°C for 10 minutes, followed
by 40 cycles at 95°C for 15 seconds and at 60°C for 60
seconds. To confirm amplification specificity, PCR products
from each primer pair were subjected to a melting curve
analysis. Amplification of the 18S RNA (Eukaryotic 18S
rRNA, Hs99999901_s1, Applied Biosystems) was per-
formed in parallel as a control for sample loading and to
allow normalization between samples. Each sample was
run in duplicate, and each experiment included three
nontemplate control wells. Relative expression levels
were determined by normalization to 18S rRNA using
REST 2009.27 Results are expressed as the mean 
SE. Primers and probes were as follows: for human
VEGF121: 5-CATAGGAGAGATGAGCTTCC-3 (for-
ward), 5-CCTCGGCTTGTCACATTTTTCT-3 (reverse), and
FAM-CAGCACAACAAATGTGAATGCAGACCA-TAMRA
(probe); for human VEGF165: 5-CATAGGAGAGAT-
GAGCTTCC-3 (forward), 5-AAGGCCCACAGGGATTT-
TCT-3 (reverse), and FAM-CAGCACAACAAATGTGAATG-
CAGACCA-TAMRA (probe); and for human VEGF189:




Formation of ROS was monitored by the conversion of non-
fluorescent 6-carboxy-27-dichlorodihydrofluorescin diac-
etate, di(acetoxymethyl ester) (H2DCF-DA) (Invitrogen) to
fluorescent 6-carboxy-2,7-dichlorofluorescein diacetate
di(acetoxymethyl ester) (DCF) (Invitrogen Molecular
Probes, San Diego, CA). Cells were preincubated with apo-
cynin, NAC, or DPI for 2 hours before loading with 5 mol/L
H2DCF-DA in serum-free medium for 30 minutes at 37°C.
After loading, cells were washed twice with PBS and incu-
bated for an additional 20 minutes at 37°C to allow for dye
de-esterification. Cells were stimulated with VEGF165 for the
described times as indicated in the figure legends. Fluores-
cence was determined using a fluorometer with an excita-
tion of 485 nm and an emission of 520 nm.
Subcellular Fractionation and Western Blot
Analysis
Membrane-bound and cytosolic proteins were separated
from choroidal ECs using the Subcellular Protein Frac-
tionation Kit (Thermo Scientific, Rockford, IL). In brief,
cells were trypsinized with trypsin-EDTA (Sigma-Aldrich),
washed with PBS, and centrifuged at 400g for 5 minutes.
Cells were then incubated in cytoplasmic extraction
buffer (Thermo Scientific) for 10 minutes at 4°C. The lysed
cells were centrifuged, and the supernatant containing
cytoplasmic proteins was removed. Likewise, mem-
brane-bound proteins were extracted using membrane
extraction buffer. Equal amounts of protein samples were
resolved by SDS-polyacrylamide gel electrophoresis and
then transferred to polyvinylidene difluoride mem-
branes (Bio-Rad Laboratories, Hercules, CA), which were
blocked with 5% blocking grade dry milk (Bio-Rad Lab-
oratories) for 1 hour before incubation with the primary
antibody. Membranes were probed with anti-p47phox
and anti-p22phox antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA) at a 1:1000 dilution. The membranes
were then incubated with horseradish peroxidase-conju-
gated secondary antibodies (Jackson ImmunoResearch,
West Grove, PA) and visualized by enhanced chemilumi-
nescence using Immobilon Western (Millipore Corpora-
tion, Billerica, MA). Digitized images of Western blots
were quantified using UN-SCAN-IT (Silk Scientific, Orem,
Utah) and normalized to -actin. The densitometric val-
ues were displayed as a ratio of p47phox/p22phox.
Rac1 Assay
After stimulation, choroidal ECs were kept on ice, washed
with ice-cold PBS, and assayed for Rac1 activation.23
Choroidal ECs were lysed in 300 l of Rac1 assay buffer
B (50 mmol/L Tris, pH 7.6, 150 mmol/L NAC, 1% Triton
X-100, and 0.5 mmol/L MgCl2) containing protease inhib-
itors and 1 mmol/L sodium vanadate. Lysates were clar-
ified by centrifugation at 13,000 rpm for 5 minutes at 4°C.
Lysates were then incubated for 30 minutes at 4°C with
gentle rocking with 30 g of GST-PBD (Rac1-binding
domain of glutathione S-transferase p21-activating ki-
nase) fusion protein immobilized on glutathione beads to
specifically pull down active (GTP-bound) Rac1. The
beads were washed four times with the same lysis buffer
and then were resuspended in 2 gel sample buffer.
Bead-bound active Rac1 and total Rac1 from reserved
cell lysates were then analyzed by SDS-polyacrylamide
gel electrophoresis. Proteins were transferred to nitrocel-
lulose membranes (Schleicher & Schuell BioScience,
Inc., Keene, NH) and processed for Western analysis
using a monoclonal antibody directed against Rac1.
Bound antibodies were detected by enhanced chemilu-
minescence. For quantification of Western blots, intensity
values of bands were measured from three different re-
peats for each experiment using ImageJ software (Na-
tional Institutes of Health, Bethesda, MD).
Small Interfering RNA Transfection
Choroidal ECs plated at approximately 50% confluence
were transfected with small interfering RNA (siRNA) to
Rac1 (Dharmacon RNA Technologies, Lafayette, CO) at
a concentration of 25 nmol/L using OligofectAMINE (In-
vitrogen) according to the manufacturer’s instructions. A
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nontargeting siRNA (Dharmacon RNA Technologies) was
used as a control. Cells were transfected for 4 hours in
serum-free medium, after which 1.5 ml of EGM-2MV was
added. Cells were harvested after 72 hours.
Migration Assay
Transwell polycarbonate plates with tissue culture inserts
containing a membrane with 8-m pores were coated
with 20 g/ml PureCol (INAMED Biomaterials, Fremont,
CA). Choroidal ECs were suspended in serum-free EBM
and seeded into each insert. The cells were then incu-
bated with 10 ng/ml of VEGF added to each of the outer
chambers. After 4 hours of incubation, ECs adhering to
the top surface of the tissue culture inserts were removed
with a cotton-tipped applicator, and ECs adhering to the
bottom surface of the inserts were trypsinized and
counted using a hemocytometer.
In Vivo Laser-Induced CNV Model
Wild-type mice (C57BL/6) were purchased from Charles
River. p47phox knockout mice have been shown to lack
p47phox by Southern analysis.28 Three-month-old mice
were used in laser-induced CNV experiments. All animals
were cared for in accordance with the University of North
Carolina’s Institute for Laboratory Animal Research (Guide
for the Care and Use of Laboratory Animals) and the Associ-
ation for Research in Vision and Ophthalmology Statement
for the Use of Animals in Ophthalmic and Vision Research.
Wild-type mice were injected intraperitoneally with 10
mg/kg/day apocynin (Sigma-Aldrich, St. Louis, MO) dis-
solved in PBS each day for 5 days preceding and 5 days
after laser treatment. The treatment and time points were
chosen based on other interventional studies for laser-in-
duced CNV29 and based on peak recruitment of macro-
phages.30,31 PBS-injected animals were used as controls.
Mice were anesthetized with 10 mg/kg ketamine and
100 mg/kg xylazine, and the pupils of each eye were
dilated with 1% topical Tropicamide (Alcon Pharmaceu-
ticals, Ft. Worth, TX). The retina was visualized via a glass
coverslip held against the cornea with Gonak (Akorn,
Lake Forest, IL) as a coupling agent using a Zeiss SL30
slit lamp biomicroscope. Laser photocoagulation (200
mW, 100 ms, 50 m) was induced in both eyes of adult
female mice using a 532-nm laser from Iridex (Irvine, CA).
Four to six laser spots were delivered, each approxi-
mately 2 disk diameters from the optic nerve with care to
avoid major vessels. Disruption of Bruch’s membrane
was confirmed by the appearance of a cavitation bubble.
Three and 5 days after injury, eyes were removed and
fixed in 4% paraformaldehyde for 1 hour. The lens, globe,
and retina were removed, and the choroid/sclera seg-
ment was cut into a cloverleaf pattern and mounted onto
a microscope slide for choroidal flat mounts. The tissue
was treated with cold 70% methanol for 20 minutes,
washed with PBS, treated with 0.1% Triton X-100 (Sigma-
Aldrich) in PBS, and washed three more times with PBS.
The segments were then incubated in Isolectin Alexa
Fluor 568 (Invitrogen) overnight at 4°C and flat-mounted
with a 1:1 PBS/glycerol mix.
Images of the flat mounts were taken with a Leica SP2
upright confocal microscope (Leica, Wetzlar, Germany). All
images were taken with a 20 objective. Multiple horizontal
sections of the choroid/sclera were taken at 1-m incre-
ments. Laser burns that were too deep (indicated by dark
areas in the center of the lesion), associated with hemor-
rhage, or co-joined with other lesions were excluded from
the analysis. The stacked images of the lesions were mea-
sured and expressed as total volumes (m3) using Volocity
5.0 (Improvision/PerkinElmer, Waltham, MA). For each ex-
periment, multiple spots from both eyes of four to five ani-
mals per condition were analyzed. All volumes calculated
were averaged as one value per animal. A maximum pro-
jection of the z-stack was created for each CNV lesion for
qualitative comparisons.
Immunohistochemical Labeling
Whole eyes were placed in Hanks’ buffered salt solution,
and the anterior segment and retina were removed. The eye
cup, consisting of RPE-choroid-sclera, was flat mounted
and dissected into small, rectangular laser burn and nonla-
ser burn sections, which were fresh frozen in Optimal Cut-
ting Temperature (O.C.T.) compound (Sakura Finetek USA,
Inc., Torrance, CA) and serially cut into 10-m sections. For
comparisons, labeled serial sections were placed onto the
same microscope slide to assure equal handling and anti-
body labeling conditions. Sections were fixed for 15minutes
in 2% paraformaldehyde, washed three times in PBS, and
incubated overnight at 4°C with Alexa Fluor 568-isolectin
B4 in PBS (1:100) to stain the vasculature. After being
washed in PBS three times, retinas were incubated for 30
minutes in 5% bovine serum albumin to block nonspecific
binding of the primary antibody. All sections were rinsed
three times in PBS and mounted in PBS/glycerol (2:1 with
Vectashield, Vector Laboratories, Burlingame, CA). On all
slides, the coverslips were sealed with nail polish, and images
of the sections were captured using a Leica SP2 scanning
laser confocal microscope and digitally stored for analysis.
Control sections were labeled with secondary antibodies only
to assess for background staining due to nonspecific binding.
ROS Detection in Retina/Choroid Sections
ROS generation was detected using dihydroethidium (DHE)
fluorescence measurement as described previously.32
Fresh-frozen sections of RPE-choroid were prepared from
eye cups as described above. Control and experimental
sections were placed on the same slide and processed
under the same conditions. Sections were thawed, washed
in Tris-buffered saline and incubated with 10 mol/L DHE
(Invitrogen) in the dark at 37°C for 15 minutes. Slides were
rinsed and mounted in PBS/glycerol (2:1 with Vectashield,
Vector Laboratories). Confocal images were acquired with
an Olympus FluoView FV500 laser scanning confocal mi-
croscope using a 20 objective and 530 nm excitation/615
nm emission filters at the same photomultiplier tube voltage,
gain, and offset. Images were converted to grayscale using
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Adobe Photoshop CS3. The area of the RPE and choroid
was measured, including the lesion area and neovascular
tissue in laser-burned sections. The sclera and extraocular
tissues were excluded from analysis. The sum of the gray
values of all pixels (integrated density) per image area of
interest was measured using ImageJ 1.43. The integrated
densities of sections of CNV from several mice were ana-
lyzed for each condition and time point. Sections for DHE
analysis were fresh-frozen and obtained within 3 hours of
staining.
Statistical Assays
For in vitro assays, experiments were performed in triplicate
with four to five samples per condition. For in vivo experi-
ments, at least four animals (eight eyes) per condition were
used. Statistics were determined with analysis of variance
and a post hoc Bonferroni t-test. For real-time PCR analy-
ses, the REST was used as described earlier.27
Results
VEGF-Induced Rac1 Activation in Choroidal ECs
VEGF was previously reported to activate Rac1
through VEGF receptor 2 in human umbilical vein en-
dothelial cells.24 We therefore examined whether
VEGF165 also caused Rac1 activation in choroidal ECs.
Rac1 GTP loading was measured by pulldown assays
with GST-PBD, followed by blotting for Rac1, as de-
scribed previously.23 We determined that Rac1 was
activated within 5 minutes of treatment with VEGF165
and remained active for 60 minutes in the choroidal






























Figure 1. VEGF treatment activates Rac1 in choroidal ECs. Choroidal ECs
were treated with 10 ng/ml VEGF for the indicated times, and the activation
of Rac1 was measured using a GST-PBD pulldown assay as described in
Materials and Methods. Total Rac1 was used as a loading control. A: Repre-
sentative blot showing increased active Rac1 within five minutes of treatment
with VEGF. B: Densitometry analysis of blots performed as described in
Materials and Methods. Band intensity is expressed for each time point as a
relative number compared with the 0-minute time point. Rac1 activation at
the zero time point is statistically different from that of cells treated with













































Figure 2. VEGF-induced ROS generation in choroidal ECs. A: Cells were
incubated with different concentrations of VEGF165 for 15 minutes and then
ROS generation was determined by DCF fluorescence measurement (*P 
0.05); 200 mol/L H2O2 was used as a positive control. B: Choroidal ECs
were pretreated with 1 mmol/L NAC, 500 mol/L apocynin (Apo), or 1
mol/L DPI for two hours. The choroidal ECs were loaded with H2DCF-DA
and then treated with 10 ng/ml VEGF165 for ten minutes. The generation of
ROS was measured by the fluorescence intensity of DCF. Data are expressed
in relative fluorescent units (RFU) as given by the plate reader. *P  0.05
when VEGF is compared with control choroidal ECs. Treatment with NAC,
DPI, or Apo abrogated VEGF-induced generation of ROS.









































Figure 3. Rac1-dependent VEGF-induced ROS in choroidal ECs. A: Choroi-
dal ECs were transfected with Rac1 siRNA or nontargeting siRNA for 72 hours.
Cells were then lysed in sample buffer, electrophoresed, and immunoblotted
with an antibody against Rac1 or actin. B: Choroidal ECs were transfected
with Rac1 siRNA or a nontargeting siRNA for 72 hours. Cells were then
treated with 10 ng/ml VEGF, and ROS generation was monitored by DCF
fluorescence. Data are expressed as relative fluorescent units (RFU) as given
by the plate reader. ROS generation in the nontargeting siRNA cells treated
with VEGF is statistically different from that in the Rac1 siRNA cells treated
with VEGF at 15 minutes (*P  0.05). Con, control.
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VEGF-Induced ROS in Choroidal ECs
It has been demonstrated that Rac1 activation can lead to
increased generation of ROS in an NADPH oxidase-depen-
dent manner.33,34 Because NADPH oxidase is an effector
for Rac1, we tested whether exposure of choroidal ECs to
different concentrations of VEGF would stimulate the gen-
eration of ROS. VEGF165 increased ROS production in cho-
roidal ECs in a dose-dependent manner, as measured us-
ing the H2DCF-DA assay (Figure 2A). The production of
VEGF-induced ROS at 15minutes was inhibited by pretreat-
ment of ECs with either of two NADPH oxidase inhibitors,
apocynin or DPI, to a similar degree as with a broad anti-
oxidant, NAC (Figure 2B).
To determine whether Rac1 was required for VEGF-
induced ROS generation in the choroidal ECs, we
knocked down Rac1 protein expression with siRNA (Fig-
ure 3A). We then compared the ability of the ECs to
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Figure 4. Rac1 activated upstream of NADPH
oxidase in VEGF-stimulated choroidal ECs. A:
Choroidal ECs were pretreated with 1 mmol/L
NAC for two hours before treatment with
VEGF165 (10 ng/ml). The activation of Rac1 was
measured through a GST-PBD pulldown assay.
Representative blots are shown for each. B: Cho-
roidal ECs were pretreated with 500 mol/L apo-
cynin for 2 hours before treatment with VEGF165
(10 ng/ml). The activation of Rac1 was measured
through a GST-PBD pulldown assay. C: Choroi-
dal ECs were pretreated with 1 mol/L DPI for
two hours before treatment with VEGF165 (10
ng/ml). The activation of Rac1 was measured
through a GST-PBD pulldown assay. Represen-
tative blots are shown for each. Densitometry
analysis of blots was performed as described in
Materials and Methods. Band intensity is ex-
pressed for each treatment as a relative number
compared with the control. Rac1 activation in
the control cells is statistically different from that
for cells treated with VEGF or VEGF  drug.
(*P  0.05). Con, control.
Figure 5. p47phox/p22phox increased in VEGF-stimulated choroidal ECs. A:
Choroidal ECs (CECs) were incubated with 30 ng/ml VEGF165 for 15 minutes,
and isolated membrane protein was separated by SDS-polyacrylamide gel elec-
trophoresis. Membranes were then blotted for p47phox or p22phox. B: Figure is
representative of densitometry analyses of Western blot of membrane protein
probed with anti-p47phox and anti-p22phox antibodies. -Actin was used as a
loading control. The ratio in control CECs is statistically different from that in






























Figure 6. NADPH oxidase required for VEGF-induced migration of choroi-
dal ECs. Endothelial cells were seeded onto collagen-coated transwell tissue
culture inserts in the presence or absence of NAC, DPI, or apocynin (Apo) for
two hours. After this initial pretreatment with inhibitors, 10 ng/ml VEGF was
added to the outer chamber, and cells were allowed to migrate for two hours.
After two hours, cells remaining on the top of the chamber were removed,
and cells that had migrated to the bottom chamber were trypsinized and
counted. Migration of the VEGF-treated choroidal ECs is statistically different
from that of the choroidal ECs treated with VEGF  drug (*P  0.05). All
values are expressed as relative to the control, which has been set equal to
1. C, control choroidal ECs.
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generate ROS after VEGF treatment in both control and
Rac1 siRNA-treated cells. In cells treated with control
siRNA, VEGF led to ROS generation, whereas in ECs
treated with Rac1 siRNA, VEGF was no longer capable of
inducing ROS production (Figure 3B). These data sug-
gest that Rac1 is required for VEGF-induced generation
of ROS in choroidal ECs and is upstream of ROS produc-
tion. To further examine the relationship between Rac1
and ROS in response to VEGF treatment, we tested
whether ROS inhibition had an effect on VEGF-induced
Rac1 activation. We found that pretreatment with either
the antioxidant NAC (1 mmol/L) or the NADPH oxidase
inhibitors, apocynin (500 mol/L) or DPI (1 mol/L), did
not reduce Rac1 activation in choroidal ECs (Figures 4,
A–C). Collectively, these data indicate that VEGF causes
Rac1-dependent generation of ROS in choroidal ECs and
that Rac1 activation is required upstream of NADPH ox-
idase in this pathway.
VEGF-Induced Activation of NADPH Oxidase
The above data demonstrate that inhibition of NADPH oxi-
dase activity attenuates VEGF-induced ROS production.
We next sought to determine whether VEGF treatment led to
the activation of NADPH oxidase in choroidal ECs. Activa-
Figure 7. Inhibition of NADPH oxidase de-
creases laser-induced CNV in mice. A: ROS lev-
els in lasered and unlasered sections of RPE-
choroid in three month-old C57BL/6 mice. ROS
levels were determined by measuring DHE flu-
orescence. Data are presented as integrated den-
sity per area (mean  SEM [10 mol/L]) using
ImageJ 1.43 for analysis. *P  0.05, laser-treated,
PBS versus apocynin (Apo), day five. B–I: Rep-
resentative images of retinal/choroidal cross sec-
tions from mice unlasered (B–E) or lasered (F–I)
and administered apocynin (D, E, H and I) or
PBS (B, C, F and G). Sections are oriented with
CNV and/or RPE-choroid at the top and the
sclera below. Phase images (B, D, F, and H)
were taken of corresponding DHE-stained im-
ages (C, E, G, and I). Note the qualitatively
increased number of DHE-stained cells in la-
sered sections (bottom row) compared with re-
spective images (top row) and qualitatively re-
duced number of DHE-stained cells in lasered
sections from apocynin-treated (I) compared
with PBS-treated (G) mice. DHE fluorescence is
found in mainly nonpigmented cells in PBS-
treated lasered mice (compare arrowheads in
phase [F] and DHE fluorescence [G]) and in both
pigmented and nonpigmented cells in both PBS-
treated (F) and apocynin-treated lasered mice
(compare arrowheads in phase [H] and DHE
fluorescence [I]). J: C57BL/6 mice (three months
old) were treated with apocynin (10 mg/kg/day)
or PBS for five days preceding and five days after
photocoagulation by laser treatment. Choroidal
flat mounts of lasered areas were stained with
lectin and 1-m horizontal sections were cap-
tured with confocal microscopy, measured, and
analyzed as described (*P  0.007, analysis of
variance). K: Representative images of maxi-
mum projections of CNV from choroidal flat
mounts are shown for each condition: left, PBS-
treated; right, apocynin-treated. Scale bar  200
m. RPE/BM, retinal pigment epithelium/
Bruch’s membrane; laser CNV, choroidal neo-
vascular lesion induced with laser injury.
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tion of NADPH oxidase occurs through assembly of cyto-
solic with membrane-bound subunits.25 Because isoforms
of the subunits can vary in different species and even tis-
sues,35 we confirmed expression of the p47phox subunit of
NADPH oxidase by Western blot in human choroidal ECs
(data not shown). We then examined the recruitment of
p22phox and p47phox to the membrane compartment
as a measure of NADPH oxidase activation25,36 in cho-
roidal ECs exposed to VEGF165. Compared with the
control, VEGF treatment led to an increase in the
p47phox/p22phox subunit ratio (Figure 5). This pro-
vides support that VEGF treatment leads to the activa-
tion of NADPH oxidase in choroidal ECs.
Inhibition of NADPH Oxidase Activity on
VEGF-Induced Migration of Choroidal ECs
The ability of ECs to migrate is a critical component of
both angiogenesis and CNV. To determine whether
NADPH oxidase might be required for VEGF-induced
choroidal EC migration, the inhibitors DPI and apocynin
and the broad spectrum antioxidant NAC were used.
Treatment with VEGF caused an approximate twofold
increase in the number of choroidal ECs that migrated
across a transwell insert compared with untreated control
ECs. However, treatment with apocynin, DPI, or NAC
significantly reduced VEGF-induced EC migration (Fig-
ure 6). These data suggest that NADPH oxidase activity
and ROS generation play an important role in regulation
of choroidal EC migration.
Production of ROS and Inhibition of NADPH
Oxidase in Laser-Induced CNV
Rac1 activation is necessary for choroidal EC transmigra-
tion across the RPE,23 a critical step in vision-threatening
neovascular AMD. Because VEGF-induced Rac1 activation
triggered downstream activation of NADPH oxidase and
contributed to choroidal EC migration, we investigated
whether inhibition of NADPH oxidase would affect the de-
velopment of CNV in the laser-induced CNV model. This
model is a widely used animal model of neovascular
AMD.30 As a measurement of superoxide radical and intra-
cellular ROS, we assayed DHE fluorescence. We treated
animals with daily 0.1-ml intraperitoneal injections of apoc-
ynin to inhibit NADPH oxidase (10 mg/kg/day) or PBS, as a
control, for 5 days before and 5 days after laser treatment to
induce CNV. Doses were based on previous studies show-
ing effective and significant reductions in retinal ROS.37
Compared with unlasered areas, DHE fluorescence was
greater in RPE-choroid areas that had received laser injury
3 days (P  0.001, analysis of variance) or 5 days previ-
ously (P  0.01, analysis of variance) (Figure 7A). Qualita-
tive assessment of ROS determined by DHE fluorescence
also revealed less DHE staining in unlasered eyes (Figure 7,
B–E) compared with respective lasered eyes (Figure 7, F–I).
Compared with mice that received control PBS, apocynin
treatment significantly reduced ROS within the RPE-choroid
of sections with laser injury at day 5 (P  0.05, analysis of
variance) (Figure 7A). Likewise, Figure 7 shows less DHE
staining in CNV in apocynin-treated (Figure 7I) compared
with control lasered eyes (Figure 7G), in which predom-
inantly nonpigmented and some pigmented cells seen in
the corresponding phase image in Figure 7F were DHE-
positive. In unlasered RPE-choroid, no significant differ-
ence was found between apocynin- and PBS-treated
mice. In addition, compared with the PBS control, apoc-
ynin significantly reduced CNV volumes measured from
lectin-stained choroidal flat mounts (P  0.007, analysis
of variance) (Figure 7J) and as noted in underlying max-
imum projections of lectin-stained CNV in choroidal flat
mounts (Figure 7K).
To confirm the role of NADPH oxidase in CNV, we sub-
jected mice lacking the p47phox subunit and hence a func-
tional NADPH oxidase to laser-induced injury. First, we ex-
amined the morphology of untreated whole-eye cross
sections of p47phox/ and wild-type counterparts that
were stained with hematoxylin and eosin at the Histology
Research Core Unit at the University of North Carolina (Fig-
ure 8). Compared with a wild-type eye, the p47phox/ eye
had no discernible structural differences in the layers of the
neurosensory retina, RPE, or choroid. In lasered regions of
p47phox/ mice, there was less DHE fluorescence at day
3 (P  0.001, analysis of variance) and day 5 (P  0.05,
analysis of variance) (Figure 9A) compared with that for
wild-type mice. A representative image (Figure 9) shows
qualitatively increased DHE fluorescence in sections from
lasered (Figure 9, F–I) versus unlasered (Figure 9, B–E)
mice. Qualitatively fewer DHE-stained cells were present in
sections from lasered p47phox knockout (Figure 9I) com-
pared with wild-type (Figure 9G) mice. In wild-type lasered
eyes, DHE fluorescence was seen predominantly in non-
pigmented (arrowheads, compare Figure 9, F and G) and
some pigmented cells, whereas in p47phox/ eyes, DHE
fluorescence was less and seen in both pigmented and
nonpigmented cells (compare Figure 9, H and I). DHE
fluorescence was not significantly different in unlasered
sections at either time point (P 	 0.05, analysis of variance).
CNV volume measured from lectin-stained choroidal flat
mounts was reduced in lasered p47phox/ compared
with wild-type mice at day 5 (P  0.036, analysis of vari-
ance) (Figure 9J) and as noted in the underlying image
Figure 8. Ocular histology of p47phox/ compared with wild-type mice.
Representative images of H&E stains of wild-type (top) and p47phox/
whole eyes (bottom). Inset: magnified retinal layers. Scale bar  200 m.
2098 Monaghan-Benson et al
AJP October 2010, Vol. 177, No. 4
(Figure 9K) of maximum projections of lectin-stained CNV in
choroidal flat mounts).
NADPH oxidase can be activated in several different
cell types involved in the development of CNV, including
choroidal ECs, RPE, and macrophages.25 RPE express
VEGF in response to age-related stimuli, including oxida-
tive stress,38 and VEGF plays an important role in CNV in
human AMD.39 To examine the role of RPE, we cultured
human ARPE-19 cells in the presence of NADPH oxidase
inhibitors, apocynin or DPI, and obtained purified RNA to
measure VEGF splice variants by real-time PCR. Com-
pared with control PBS treatment, both apocynin and DPI
significantly reduced expression of all VEGF splice variants
(Figure 10A). This result suggests that NADPH oxidase
activation in RPE plays a role in the expression of VEGF.
We also labeled tissue sections of CNV from wild-type
mice that had received laser injury 5 days previously.
Fresh sections were stained with DHE to detect ROS.
Phase images of the same sections revealed mainly non-
pigmented and some pigmented cells that were DHE-
positive. In adjacent fixed sections, lectin-stained vascu-
lar cells seemed to correspond to nonpigmented DHE
positive cells (Figure 10, B–D).
Discussion
Previous studies have reported that external stimuli leading
to ROS generation15,16,40,41 contribute to the pathophysiol-
ogy in AMD. However, much of the evidence in vivo has
supported a role of ROS in early or atrophic forms of AMD
or retinal degeneration.16,42 Our data provide evidence that
activation of NADPH oxidase in vivo is also important in
neovascular AMD and that subunits p47phox and Rac1
Figure 9. Deficiency in the p47phox subunit of
NADPH oxidase decreases laser-induced CNV
in mice. A: Three-month-old wild-type and
p47phox/ mice received photocoagulation by
laser treatment. ROS levels in lasered and unla-
sered sections of RPE-choroid were determined
by measuring DHE fluorescence. Data are pre-
sented as integrated density per area (mean 
SEM, DHE [10 mol/L] using ImageJ for analy-
sis). *Analysis of variance, P  0.05, day three
and day five, laser-treated, wild-type versus
p47phox/ mice. B–I: Representative images
of retinal-choroidal cross sections from mice un-
treated (top row) or laser-treated (bottom row).
Phase images (B, D, F, and H) were taken of
corresponding DHE-stained images (C, E, G,
and I). Sections from wild-type mice (B, C, F and
G) or p47phox/ mice (D, E, H and I). Sections
are oriented with CNV and/or the RPE-choroid at
the top and sclera (nonpigmented layer) at the
bottom. An edge artifact is noted at the inferior
boundary of the sclera in G. Note the qualita-
tively increased number of DHE-stained cells in
lasered sections (F–I) compared with unlasered
respective comparisons (B–E) and qualitatively
fewer DHE-stained cells in lasered sections from
p47phox/ mice (I) compared with wild-type
mice (G). DHE fluorescence is found in mainly
nonpigmented cells in wild-type lasered mice
(compare arrowheads in phase [F] and DHE
fluorescence [G]) and in both pigmented and
nonpigmented cells in p47phox/ lasered mice
(compare phase [H] and DHE fluorescence [I]).
J: Wild-type and p47phox/ mice received
photocoagulation by laser treatment 5 days ear-
lier. Choroidal flat mounts of lasered areas were
stained with lectin and 1-m horizontal sections
were captured with confocal microscopy, mea-
sured, and analyzed as described (analysis of vari-
ance, *P  0.036, laser treated wild-type versus
p47phox/ mice). K: Representative images of
maximum projections of lectin-stained CNV in
choroidal flat mounts shown below: left, wild-
type; right, p47phox/. Scale bar  200 m. WT,
wild-type; RPE/BM, retinal pigment epithelium/
Bruch’s membrane; laser CNV, choroidal neovas-
cular lesion induced with laser injury.
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may play complementary roles in the complex development
of CNV.
Laboratory research using the well accepted laser-in-
duced CNV model provided evidence that VEGF was es-
sential in the development of CNV, and clinical experience
has since confirmed the importance of VEGF in human
neovascular AMD.43 We found that VEGF165 stimulated the
generation of ROS from cultured choroidal ECs. This oc-
curred through the activation of Rac1, which triggered
downstream activation of NADPH oxidase. A pathway has
been characterized in human umbilical vein endothelial
cells, in which engagement of the VEGF receptor 2 stimu-
lates the Rac1 guanine nucleotide exchange factor,
Vav2.24,44 In pulmonary microvascular ECs, it was demon-
strated that VEGF led to Rac1 activation, stimulating the
subsequent activation of NADPH oxidase.45 Active Rac1
facilitates ECmigration through the formation of lamellipodia
and directed cell motility.46 Further, activation of Rac1 in
choroidal ECs was found to be essential for choroidal ECs
to migrate across a monolayer of RPE toward a VEGF
gradient.23 In this study, we showed that Rac1-induced
NADPH oxidase activation and ROS generation enhanced
migration of choroidal ECs toward a VEGF gradient. This
result suggests that Rac1 uses both its well known effects
on the cytoskeleton and its ability to induce ROS-dependent
signaling to maximally regulate migration.
The in vivo evidence using the laser-induced model in the
current study provides support that activation of NADPH
oxidase contributes to the formation of CNV. NADPH oxi-
dase becomes activated as a result of aggregation of mem-
brane bound and cytosolic subunits.25 Heumüller et al47
have reported that apocynin works mainly as an antioxidant
in cultured ECs, because it requires ROS to become active,
and ECs lack myeloperoxidases that activate apocynin.
However, in vivo, apocynin is a strong NADPH oxidase
inhibitor, believed in part to be due to its activation by
myeloperoxidases in cells adjacent to ECs, such as mac-
rophages.25 We found that inhibition of NADPH oxidase
with apocynin or knockout of subunit p47phox was associ-
ated with reduced DHE fluorescence in association with a
reduction in CNV volume after laser injury.
Activation of NADPH oxidase can occur in multiple cells
involved in the development of CNV including choroidal
ECs, RPE, and macrophages.48–50 VEGF is released from
RPE and macrophages and has been localized in CNV
lesions.51 ROS exposure to cultured RPE enhanced VEGF
release.52 Li et al50 reported that knockdown of the NADPH
oxidase subunit p22phox in RPE cells inhibited laser-in-
duced CNV in mice. These investigators proposed that
p22phox knockdown reduced ROS generation from RPE-
derived NADPH oxidase and therefore led to reduced
VEGF production. In agreement with this study, we found
significant inhibition of VEGF mRNA expression with two
different inhibitors of NADPH oxidase, suggesting that
NADPH oxidase does stimulate enhanced VEGF produc-
tion from RPE cells. Investigators have also reported an
influx of F4/80 macrophages in laser-induced CNV that
peaked at day 3 and then were reduced when CNV devel-
oped.30 We found that DHE fluorescence appeared in both
pigmented and nonpigmented cells within CNV lesions,
and some cells also appeared to stain with lectin. Qualita-
tively, fewer DHE-stained cells appeared in CNV lesions of
both apocynin-treated mice and p47phox/ mice com-
pared with the respective controls, and this result corre-
Figure 10. A: Inhibition of ROS generation de-
creases expression of VEGF splice variants in
human RPE. Total RNA was extracted from hu-
man ARPE treated with PBS, apocynin (Apo), or
DPI. Changes in gene expression were detected
by real-time PCR. Data are presented as mean 
SEM change in gene expression normalized to
18s RNA levels and relative to PBS control nor-
malized to 18s levels. *P  0.01; **P  0.001
versus PBS control, n  10 (analyzed with REST
software). Apo, apocynin. B–D: Panels of cross
sections through the CNV lesion 5 days after
laser treatment in wild-type mice. Sections taken
in 10-m increments are shown. B: Phase image
showing pigmented and nonpigmented cells
(neurosensory retina is removed and the sclera is
toward the bottom of the image) of a fresh tissue
section that had been stained for DHE fluores-
cence and imaged previously (C). D: Adjacent
section through the same CNV lesion fixed and
stained with lectin to visualize vascular cells.
Arrowheads indicate lectin-stained tissue in D
corresponding to DHE-positive cells in C. Scale
bar  80 m.
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sponded to measured DHE fluorescence in these groups.
Collectively, these data suggest roles for multiple cells in the
development of CNV. Further studies are necessary to de-
termine the roles of each individual cell type in the regula-
tion of CNV.
The pathology of AMD is complex and occurs in the outer
retina in the region of the RPE, Bruch’s membrane, and the
choroid. Neovascular AMD accounts for 90% of the legal
blindness that occurs in AMD.38 Vision loss from neovas-
cular AMD occurs with CNV, in which blood vessels origi-
nating from the choroidal vasculature and choriocapillaris
grow into the neurosensory retina. Activated choroidal ECs
must migrate through Bruch’s membrane toward the RPE.
There is evidence that VEGF released from the basal RPE is
an important chemoattractant for migrating choroidal
ECs53,54 and that the RPE cell junctions break down with
RPE-EC contact.55 It is believed that breakdown of the RPE
barrier permits VEGF to enter the neurosensory retinal
space and attract choroidal ECs to form neurosensory ret-
inal CNV. Neurosensory retinal CNV is associated with dis-
ruption of the architecture of the neurosensory retina and
leakage of fluid and blood substances into the neurosen-
sory retina, all of which reduce visual acuity. Clinically,
vision is restored to some degree by reduction of fluid
leakage into the neurosensory retinal layers, and the current
leading pharmacological intervention is inhibition of the per-
meability and growth factor, VEGF.56 It is known that VEGF
is increased in laser-induced injury models and in human
specimens of CNV.39 Treatment with anti-VEGF agents has
improved the management of neovascular AMD but is only
effective in approximately 40% of eyes and requires re-
peated intraocular injections. There is also concern of pos-
sible toxicity from inhibiting the beneficial57–61 while treating
the pathological functions of VEGF. Intervening down-
stream of VEGF, through NADPH oxidase or Rac1, may
provide more effective and safer therapies.
In summary, we provide evidence that NADPH oxidase
plays a role in neovascular AMD and may affect several cell
types involved in the development of CNV. A plausible
scenario is that age-related stresses induce RPE to express
VEGF. Soluble VEGF activates and acts as a chemoattrac-
tant to direct migration of choroidal ECs.23 The activation of
Rac1 in choroidal ECs is followed by downstream activation
of NADPH oxidase and generation of ROS. The ROS from
the choroidal ECs may then induce RPE or macrophages to
express VEGF, thereby leading to a positive feedback loop
and contributing to the pathology of neovascular AMD.
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